Utilizing Biomarkers to Measure Changes in Neuroinflammation & Neurodegeneration to Validate Safety & Efficacy in ALS Clinical Trials

Time: 9:40 am
day: Day Two AM


• Rationale for targeting the LINE-1 reverse transcriptase against ALS and FTD

• Exploring biomarkers to measure changes in neuroinflammation and neurodegeneration

• Contextualizing biomarker usage for safety and efficacy measurements in phase 2a clinical trials